Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Trial Profile

A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Oct 2018

At a glance

  • Drugs AB-928 (Primary) ; GLS 010 (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors Arcus Biosciences
  • Most Recent Events

    • 10 Aug 2018 Status changed from planning to recruiting.
    • 09 May 2018 According to an Arcus Biosciences media release, company has submitted regulatory filing to initiate this trial and expect to initiate dosing in patients in mid-2018.
    • 17 Apr 2018 According to an Arcus Biosciences media release, data from dose-escalation portion is expected in the first half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top